The application period for the Ann B. Bussel Research Award for the July 1, 2024 – June 30, 2026 award period is closed.
In 2024, applications for the Ann B. Bussell Award were accepted and reviewed in collaboration with the Duke/UNC Alzheimer’s Disease Research Center (ADRC) RC).
The Ann B. Bussell Research (ABB) Award, funded directly by the Ruth K. Broad Biomedical Research Foundation, will make a two-year $100,000 yearly award. This award will reopen for applications in the fall of 2025.
The Ann B. Bussel Research Award is named in honor of a long-time board member of the Ruth K. Broad Biomedical Research Foundation, in recognition of her thirty-year commitment to funding and supporting creative research efforts directed at understanding and treating Alzheimer’s disease at Duke and other research institutions.
**Please read the eligibility criteria for the Ann B. Bussel and Developmental Project awards carefully, as they are slightly different. Applicants with a proposal that is eligible for both the ABB and the DP mechanisms have the opportunity to submit a single application, which will be first considered for the ABB award and if not selected for the ABB award, automatically receive consideration for funding by the ADRC DP program. Applicants may also submit different project proposals for each mechanism, provided there is no scientific overlap in the proposed projects.
For questions about the Ruth K. Broad Foundation, please contact Cathleen Durgin, Secretary, at cathleen.durgin@duke.edu.
The following are courtesy announcements on behalf of the Duke/UNC ADRC. These awards are not funded by or selected by the Ruth K. Broad Foundation.
Developmental Projects (DP) Request for Applications 2023
The goal of the ADRC developmental project program is to stimulate and support innovative, high potential lines of research related to our theme: to identify age-related changes across the lifespan that contribute to the development, progression, or experience of AD. DP awardees are supported by the ADRC Cores listed above. Awardees are expected to pursue external funding in their research area and applications should convey the plan to use findings from the developmental project to inform or justify future applications.
REC Scholar Request for Applications 2023
The goal of the ADRC Research Education Component (REC) is to promote the development of future research leaders who are conducting basic, translational, or clinical AD+ADRD research within the focus area of age-related changes across the lifespan. The REC will award up to 4 REC Scholar awards annually, of 2-year duration, with funding beginning July 1, 2024. The award can cover salary, project support, and research career development activities. REC Scholars are supported by the ADRC Cores listed above, and meet regularly with a mentorship team including ADRC Investigators. At the conclusion of the award, REC Scholars are expected to pursue external funding in their research area.
ADRC RFP for innovative neurodegeneration-related discovery research in Basic Brain Science
The Duke/UNC Alzheimer’s Disease Research Center is pleased to announce a call for proposals for high risk/high impact, basic, discovery science relevant to neurodegeneration. Priority will be given to faculty in the Duke University School of Medicine researching basic neurobiology that has a plausible link to understanding neurodegeneration, including (but not limited to) Alzheimer’s Disease. This opportunity is made possible by a philanthropic gift to Duke University School of Medicine, and eligible applicants must have a faculty appointment at Duke.
We plan to make one $100,000 award focused on truly innovative basic science pilot research projects in neuroscience, based on the following criteria:
- Relevance to neurodegeneration
- Originality
- Scientific rationale
- Clear articulation of the way in which the proposed research differs from other funded projects of the Principal Investigator
- Clarity of plans for obtaining subsequent extramural funding to extend or complete the project
- Feasibility to complete the proposed work within one year of receipt of funding; extensions are not guaranteed.
Applications may use or develop any model system, including animal models, human tissue, or human brain models. Innovation, relevance to neurodegeneration, and the plausibility of a transition to disease-modifying science will be emphasized in the review criteria.
